{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:45:38Z","timestamp":1780339538154,"version":"3.54.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The optimal evidence-based management for the subsets of locally advanced esophageal squamous cell carcinoma (ESCC) patients who rejected or were intolerant to intravenous chemotherapy due to old age or serious comorbidities is currently lacking. This study aimed to assess the safety and local control rate (LCR) of S-1 (tegafur\u2013gimeracil\u2013oteracil potassium) combined with radiotherapy in these subsets of ESCC\u00a0patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Locally advanced ESCC patients who rejected or were intolerant to intravenous chemotherapy due to age &amp;gt;75 years or serious comorbidities were enrolled in a prospective, single-arm, phase 2 trial. The patients were treated with definitive concurrent chemoradiotherapy with S-1, which was administered orally twice daily for 28 days. The radiotherapy dose was 61.2 Gy delivered in 34 fractions. The primary end-point was the 3-year LCR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred five ESCC patients were recruited between March 2013 and October 2015. At the median follow-up of 73.1 months (IQR 65.5\u201381.4 months), 3-year LCR was 61.1%, and 1, 3, and 5-year overall survival was 77.9, 42.3, and 24.8% respectively. For safety analysis, \u2265grade 3 acute adverse events included thrombocytopenia (6.7%), leukopenia (2.9%), anemia (1.0%), anorexia (1.0%), fatigue (10.5%), hiccup (1.0%), pneumonitis (4.8%), and esophagitis (3.8%). Two patients (1.9%) died of late esophageal hemorrhage, and one patient (1.0%) died of late radiation-induced\u00a0pneumonitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>S-1 is a promising regimen in concurrent chemoradiotherapy with low toxicity and a favorable LCR in ESCC patients who rejected or were intolerant to intravenous chemotherapy due to old age or serious comorbidities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial Registration<\/jats:title><jats:p><jats:uri>ClinicalTrials.gov<\/jats:uri>, NCT01831531.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.839765","type":"journal-article","created":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T13:13:08Z","timestamp":1649164388000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Long-Term Results of a Phase 2 Study of Definitive Chemoradiation Therapy Using S-1 for Esophageal Squamous Cell Carcinoma Patients Who Were Elderly or With Serious Comorbidities"],"prefix":"10.3389","volume":"12","author":[{"given":"Yun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaying","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dashan","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiquan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuqing","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihsuan","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuaile","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21338","article-title":"Cancer Statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1623","article-title":"Chemoradiotherapy of Locally Advanced Esophageal Cancer: Long-Term Follow-Up of a Prospective Randomized Trial (RTOG 85-01)","volume":"281","author":"Cooper","year":"1999","journal-title":"Radiat Ther Oncol Group JAMA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70259-1","article-title":"Fluorouracil Versus Combination of Irinotecan Plus Cisplatin Versus S-1 in Metastatic Gastric Cancer: A Randomised Phase 3 Study","volume":"10","author":"Boku","year":"2009","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-010-9594-0","article-title":"S-1-Based Therapy Versus 5-FU-Based Therapy in Advanced Gastric Cancer: A Meta-Analysis","volume":"28","author":"Huang","year":"2011","journal-title":"Med Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1442-2050.2008.00837.x","article-title":"Concurrent Chemoradiotherapy With S-1 and Cisplatin in Advanced Esophageal Cancer","volume":"21","author":"Cho","year":"2008","journal-title":"Dis Esophagus"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1159\/000348383","article-title":"Concurrent Chemoradiotherapy With a Novel Fluoropyrimidine, S-1, and Cisplatin for Locally Advanced Esophageal Cancer: Long-Term Results of a Phase II Trial","volume":"84","author":"Iwase","year":"2013","journal-title":"Oncology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1007-3639.2015.03.012","article-title":"Outcomes and Clinical Prognostic Factors for Elderly Patients With Esophageal Squamous Cell Carcinoma Treated After Definitive Radio(Chemo)Therapy","volume":"25","author":"Lv","year":"2015","journal-title":"China Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02122","article-title":"Comparing Paclitaxel Plus Fluorouracil Versus Cisplatin Plus Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Cancer: A Randomized, Multicenter, Phase III Clinical Trial","volume":"37","author":"Chen","year":"2019","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6727","article-title":"Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress","volume":"30","author":"Scher","year":"2012","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2013-0178","article-title":"Management of Localized Esophageal Cancer in the Older Patient","volume":"19","author":"Won","year":"2014","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13592","article-title":"Is Concurrent Chemotherapy With Radiotherapy for Esophageal Cancer Beneficial in Patients Aged 80 Years or Older","volume":"39","author":"Jingu","year":"2019","journal-title":"Anticancer Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.02.097","article-title":"Definitive Chemoradiation Therapy for Esophageal Cancer in the Elderly: Clinical Outcomes for Patients Exceeding 80 Years Old","volume":"98","author":"Xu","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12885-019-6461-z","article-title":"Does Chemoradiotherapy Benefit Elderly Patients With Esophageal Squamous Cell Cancer? A Propensity-Score Matched Analysis on Multicenter Data (3JECROG R-03a)","volume":"20","author":"Chen","year":"2020","journal-title":"BMC Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-020-00725-w","article-title":"Chemoradiotherapy and Radiotherapy Alone in Patients With Esophageal Cancer Aged 80 Years or Older Based on the Comprehensive Registry of Esophageal Cancer in Japan","volume":"17","author":"Jingu","year":"2020","journal-title":"Esophagus"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2019.08.009","article-title":"Safety of Radiotherapy With Concurrent Docetaxel in Older Patients With Esophageal Cancer","volume":"11","author":"Kawamoto","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2018.02.010","article-title":"Feasibility of Definitive Chemoradiation Therapy With Nedaplatin and 5-Fluorouracil in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Retrospective Study","volume":"3","author":"Watanabe","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604749","article-title":"Safety and Outcome of Definitive Chemoradiotherapy in Elderly Patients With Oesophageal Cancer","volume":"99","author":"Tougeron","year":"2008","journal-title":"Br J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/1759-7714.12536","article-title":"Feasibility and Efficiency of Concurrent Chemoradiotherapy With Capecitabine and Cisplatin Versus Radiotherapy Alone for Elderly Patients With Locally Advanced Esophageal Squamous Cell Carcinoma: Experience of Two Centers","volume":"9","author":"Chen","year":"2018","journal-title":"Thorac Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/1759-7714.12536","article-title":"Feasibility and Efficiency of Concurrent Chemoradiotherapy With a Single Agent or Double Agents vs Radiotherapy Alone for Elderly Patients With Esophageal Squamous Cell Carcinoma: Experience of Two Centers","volume":"8","author":"Huang","year":"2019","journal-title":"Cancer Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/jca.20835","article-title":"Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients","volume":"8","author":"Zhao","year":"2017","journal-title":"J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S107668","article-title":"Long-Term Results of Definitive Concurrent Chemoradiotherapy Using S-1 in the Treatment of Geriatric Patients With Esophageal Cancer","volume":"9","author":"Lv","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.20938","article-title":"A Phase II Study of S-1 With Concurrent Radiotherapy in Elderly Patients With Esophageal Cancer","volume":"8","author":"Ji","year":"2017","journal-title":"Oncotarget"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01499","article-title":"S-1-Based Chemoradiotherapy Followed by Consolidation Chemotherapy With S-1 in Elderly Patients With Esophageal Squamous Cell Carcinoma: A Multicenter Phase II Trial","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.2705","article-title":"Efficacy of Concurrent Chemoradiotherapy With S-1 vs Radiotherapy Alone for Older Patients With Esophageal Cancer: A Multicenter Randomized Phase 3 Clinical Trial","volume":"7","author":"Ji","year":"2021","journal-title":"JAMA Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"100736","DOI":"10.1016\/j.tranon.2019.12.008","article-title":"Comparison of a Concurrent Fluorouracil-Based Regimen and a Taxane-Based Regimen Combined With Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma","volume":"13","author":"Huang","year":"2020","journal-title":"Transl Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-015-0275-8","article-title":"Phase II Study of a Platinum-Based Adapted Chemotherapy Regimen Combined With Radiotherapy in Patients 75 Years and Older With Esophageal Cancer","volume":"32","author":"Servagi-Vernat","year":"2015","journal-title":"Drugs Aging"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.5732\/cjc.010.10250","article-title":"Treatment Guideline of Radiotherapy for Chinese Esophageal Carcinoma (Draft)","volume":"29","year":"2010","journal-title":"Chin J Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2005.04.008","article-title":"Prognostic Impact of Increasing Age and Co-Morbidity in Cancer Patients: A Population-Based Approach","volume":"55","author":"Janssen-Heijnen","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1186\/s12885-019-5544-1","article-title":"A Multicenter Phase III Study Comparing Simultaneous Integrated Boost (SIB) Radiotherapy Concurrent and Consolidated With S-1 Versus SIB Alone in Elderly Patients With Esophageal and Esophagogastric Cancer - the 3JECROG P-01 Study Protocol","volume":"19","author":"Li","year":"2019","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.839765\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T13:13:17Z","timestamp":1649164397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.839765\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":29,"alternative-id":["10.3389\/fonc.2022.839765"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.839765","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,5]]},"article-number":"839765"}}